Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%

Aim Vaccine (HKG:6660) submitted pre-applications for clinical trials for two vaccines on Thursday, according to two separate Hong Kong bourse filings on the same day. These include the quadrivalent i

MT NewswiresMar 28 01:28 ET

Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%

Aim Vaccine (HKG:6660) booked an attributable loss of 1.3 billion yuan in 2023, up 307.1% from 319.6 million yuan the prior year, according to a Thursday Hong Kong bourse filing. Loss per share for th

MT NewswiresMar 28 00:40 ET

Aimei Vaccine (06660) has submitted a pre-application for clinical trials of Haemophilus influenzae type b (Hib) conjugate vaccine

The Le Méridien vaccine (06660) was announced. The group submitted Haemophilus influenzae type b (H...

Zhitong FinanceMar 27 20:12 ET

The Le Méridien vaccine (06660) has entered a major year of intensive reporting, and the mRNA technology platform lays out multiple popular vaccines

The Zhitong Finance App learned that on March 28, Emmy Vaccine (06660) released the 2023 results and several major new product development announcements. The data...

Zhitong FinanceMar 27 20:04 ET

AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Futu NewsMar 27 20:02 ET · Announcements

Another major iterative upgrade of the rabies vaccine submitted for clinical trials, and the Le Méridien vaccine (06660) has entered a major reporting year

The Zhitong Finance App learned that the Emmy Vaccine (06660) announced on the evening of the 26th that the company has recently submitted a pre-clinical trial application for a novel, high-cost human diploid rabies vaccine. This is another major milestone in Emmy Vaccine's promotion of mad vaccine development according to the established strategy after the layout of the iterative upgrade series of rabies vaccines was completed at the beginning of this month. Major manufacturers of Mad Miao are making efforts to lead the global industry's in-depth technological iterative upgrading. According to the announcement, Le Méridien's novel process is an efficient and affordable human diploid rabies vaccine, which has many innovative points. It was the first to break through the traditional technical bottleneck of the low virus titer and low yield of this process, and carried it out in the purification process

Zhitong FinanceMar 26 20:44 ET